Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Esperion Therapeutics

Esperion Therapeutics
2008 FOUNDED
PUBLIC STATUS
71-80 EMPLOYEES
ESPR STOCK SYMBOL
1 INVESTMENTS
$49.66 SHARE PRICE (As of Friday Closing)
Description

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm has Business of researching, developing and commercializing therapies for the treatment of patients with the elevated LDL-C operating segment.

Formerly Known As
HDL Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Delivery
Stock Exchange
NAS
Primary Office
  • 3891 Ranchero Drive
  • Suite 150
  • Ann Arbor, MI 48108
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Esperion Therapeutics’s full profile, request a free trial.

Esperion Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$33.13 - $54.94 $1.36B $51.35 -$3.54 417K 27.3M

Esperion Therapeutics Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 695,809 1,074,088 1,522,968 75,406
Revenue 147,382 0 0 0
EBITDA (90,898) (201,445) (166,530) (74,326)
Net Income (95,258) (201,810) (166,988) (74,978)
Total Assets 255,270 143,451 277,835 245,213
Total Debt 1,087 0 1,045 2,731
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Esperion Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Esperion Therapeutics‘s full profile, request access.

Request full access to PitchBook

Esperion Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Esperion Therapeutics‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Esperion Therapeutics Competitors (50)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dicerna Pharmaceuticals Formerly VC-backed Cambridge, MA 00 00000 000000000 00000
000 00000000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
00000000 000000000 Formerly VC-backed Allschwil, Switzerland 0000 00000 000000&0 00000
000000000000 Corporate Backed or Acquired Staines-Upon-Thames, United Kingdom 0000 00.00 000000000000 00.00
00000000 Formerly VC-backed Malvern, PA 00 00000 00000000 00000
To view this company’s complete list of competitors, request access »

Esperion Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 000000000 28-Apr-2008 000000000000000000 000 Drug Discovery
To view this company’s complete investment and acquisition history, request access »

Esperion Therapeutics Executive Team (13)

Name Title Board
Seat
Contact
Info
Timothy Mayleben Chief Executive Officer & Board Member
Rick Bartram Chief Financial Officer
Narendra Lalwani Ph.D Executive Vice President, Research & Development & Chief Operating Officer
Regina Cavaliere Chief Ethics and Compliance Officer
Ashley Hall Chief Development Officer

6 Former Executives

You’re viewing 5 of 13 executives. Get the full list »

Esperion Therapeutics Board Members (16)

Name Representing Role Since Contact
Info
Antonio Gotto Jr. Self Board Member 000 0000
Daniel Janney Alta Partners Board Member 000 0000
Dov Goldstein MD Aisling Capital Board Member 000 0000
Jay Shepard Self Board Member 000 0000
Jeffrey Berkowitz JD Self Board Member 000 0000

5 Former Board Members

You’re viewing 5 of 16 board members. Get the full list »